Rena Conti

Associate Professor, Markets, Public Policy, and Law Associate Research Director, Institute for Health System Innovation and Policy
  • Phone 617-353-1156
  • Office 514B
  • BOSTON UNIVERSITY
    Questrom School of Business
    Rafik B. Hariri Building
    595 Commonwealth Avenue
    Boston, MA 02215

  • Download CV
    Publications
  • Conti, R. (2018). "Diversity of Participants in the 340B Drug Pricing Program for US Hospitals", Journal of the American Medical Association Internal Medicine, 178 (8), 1124–27
  • Conti, R. (2018). "Out-of-Pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014", Journal of General Internal Medicine , 178 (4), 133-140
  • Conti, R. (2018). "Generic Prescription Drug Price Increases: Which Products Will Be Affected by Proposed Anti-Gouging Legislation", Journal of Pharm Policy Practice, 11 (1), 29
  • Conti, R. (2017). "Out-of-Pocket Spending among Commercially Insured Patients for Epinephrine Autoinjectors between 2007 and 2014", Journal of the American Medical Association Internal Medicine, 176 (2), 736–39
  • Conti, R. (2017). "Mitigating Financial Toxicity among US Patients with Cancer", Journal of the American Medical Association Oncology, 3 (6), 765–66
  • Conti, R. (2017). "Association of Prescription Drug Price Rebates in Medicare Part D with Patient Out-of-Pocket and Federal Spending", Journal of the American Medical Association Internal Medicine, 177 (8), 1185–88
  • Conti, R. (2017). "Biosimilars: Reimbursement Issues in Your Oncology Practice", Journal of Oncology Practice, 13 (9), 12s–14s
  • Conti, R. (2017). "Effect of FDA Investigation on Opioid Prescribing to Children after Tonsillectomy/Adenoidectomy", Pediatrics, 140 (6), 6
  • Conti, R. (2017). "Appropriately Framing Child Health Care Spending: A Prerequisite for Value Improvement", Journal of the American Medical Association, 319 (11), 1087–88
  • Conti, R. (2016). "? Conti, RM. “The Advantages of Awarding the Federal Government Negotiating Power over the Prices of Prescription Drugs—Point-Counterpoint: Should Medicare Regulate the Price of Prescription Drugs?”", Journal of Policy Analysis and Management, 35 964–70
  • Conti, R. (2016). "Response to Joyce and Sood: Why Medicare Price Negotiation Is the Wrong Prescription for Rising Drug Spending, Point-Counterpoint: Should Medicare Regulate the Price of Prescription Drugs?", Journal of Policy Analysis and Management, 35 972–74
  • Conti, R. (2016). "Pharmaceutical Policy Reform—Balancing Affordability with Incentives for Innovation", New England Journal of Medicine, 35 (8), 703–06
  • Conti, R. (2016). "Overspending Driven by Oversized Single Dose Vials of Cancer Drugs", British Journa of Medicine, 352 i788
  • Conti, R. (2016). "National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions", Journal of Urology, 195 (5), 1383–89
  • Conti, R. (2016). "Medication Adherence among HIV/AIDS Patients Receiving 340B-Purchased Antiretroviral Medications", Value in Health, 19 (3), A8
  • Conti, R. (2016). "A Pathway through the Bundle Jungle", Journal of Oncology Practice, 12 (6), 504–09
  • Conti, R. (2016). "Cost-Effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States", Journal of the National Cancer Institute, 108 (7), 234
  • Conti, R. (2016). "21st Century Pharmacovigilance: Efforts, Roles, and Responsibilities.", Lancet Oncology, 17 (11), e486–e492
  • Conti, R. (2016). "Pharmaceuticals and Public Health", Journal of the American Medical Association, 316 (20), 2083–84
  • Conti, R. (2016). "Policy Diffusion across Disparate Disciplines: Private-and Public-Sector Dynamics Affecting State-Level Adoption of the ACA", Journal of Health Politics, Policy, and Law, 40 (2), 377–85